Welcome to LookChem.com Sign In|Join Free

CAS

  • or

21873-51-8

Post Buying Request

21873-51-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

21873-51-8 Usage

General Description

4-hydroxy-6-iodoquinoline is a chemical compound with the molecular formula C9H6INO. It is a derivative of quinoline, with a hydroxyl group and an iodine atom attached to different carbon atoms in the quinoline ring. 4-hydroxy-6-iodoquinoline has been studied for its potential use as a pharmaceutical agent, particularly for its antiviral and antibacterial properties. It has also been investigated for its potential use in organic synthesis and as a building block for more complex chemical compounds. 4-hydroxy-6-iodoquinoline has also been studied for its ability to chelate metal ions, making it useful in analytical chemistry and metal extraction processes. Overall, this compound has a range of potential applications in various fields of chemistry and medicine.

Check Digit Verification of cas no

The CAS Registry Mumber 21873-51-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,8,7 and 3 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 21873-51:
(7*2)+(6*1)+(5*8)+(4*7)+(3*3)+(2*5)+(1*1)=108
108 % 10 = 8
So 21873-51-8 is a valid CAS Registry Number.

21873-51-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-iodo-6H-quinolin-4-one

1.2 Other means of identification

Product number -
Other names 6-IODO-1,4-DIHYDROQUINOLIN-4-ONE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:21873-51-8 SDS

21873-51-8Relevant articles and documents

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Zhang, Li,Cheng, Chen,Li, Jing,Wang, Lili,Chumanevich, Alexander A.,Porter, Donald C.,Mindich, Aleksei,Gorbunova, Svetlana,Roninson, Igor B.,Chen, Mengqian,McInnes, Campbell

supporting information, p. 3420 - 3433 (2022/02/16)

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

Haile, Pamela A.,Casillas, Linda N.,Bury, Michael J.,Mehlmann, John F.,Singhaus, Robert,Charnley, Adam K.,Hughes, Terry V.,Demartino, Michael P.,Wang, Gren Z.,Romano, Joseph J.,Dong, Xiaoyang,Plotnikov, Nikolay V.,Lakdawala, Ami S.,Convery, Maire A.,Votta, Bartholomew J.,Lipshutz, David B.,Desai, Biva M.,Swift, Barbara,Capriotti, Carol A.,Berger, Scott B.,Mahajan, Mukesh K.,Reilly, Michael A.,Rivera, Elizabeth J.,Sun, Helen H.,Nagilla, Rakesh,Lepage, Carol,Ouellette, Michael T.,Totoritis, Rachel D.,Donovan, Brian T.,Brown, Barry S.,Chaudhary, Khuram W.,Gough, Peter J.,Bertin, John,Marquis, Robert W.

supporting information, p. 1039 - 1044 (2018/10/15)

RIP2 kinase was recently identified as a therapeutic target for a variety of autoimmune diseases. We have reported previously a selective 4-aminoquinoline-based RIP2 inhibitor GSK583 and demonstrated its effectiveness in blocking downstream NOD2 signaling in cellular models, rodent in vivo models, and human ex vivo disease models. While this tool compound was valuable in validating the biological pathway, it suffered from activity at the hERG ion channel and a poor PK/PD profile thereby limiting progression of this analog. Herein, we detail our efforts to improve both this off-target liability as well as the PK/PD profile of this series of inhibitors through modulation of lipophilicity and strengthening hinge binding ability. These efforts have led to inhibitor 7, which possesses high binding affinity for the ATP pocket of RIP2 (IC50 = 1 nM) and inhibition of downstream cytokine production in human whole blood (IC50 = 10 nM) with reduced hERG activity (14 μM).

AMINO-QUINOLINES AS KINASE INHIBITORS

-

Paragraph 0157; 0159, (2015/09/23)

Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 21873-51-8